Quadrant HealthCom buys Dowden journals

Share this article:

Quadrant HealthCom purchased the journals division of Dowden Health Media from Lebhar-Friedman. Terms of the deal were not disclosed.

The transaction, brokered by media bankers Desilva + Phillips, closed yesterday. It gives Quadrant HealthCom four Dowden Professional Publications journals – OBG Management, Current Psychiatry, The Journal of Family Practice and Mayo Clinic Proceedings – along with Dowden's events division. About 30 Dowden employees will relocate to Quadrant's headquarters in Parsippany, NJ.

Quadrant president Stephen Stoneburn said in a statement: “We are excited about the opportunity to add leading properties in new therapeutic and audience markets and to expand our already strong presence in the women's healthcare sector.”

Quadrant's stable of nine journals includes The Female Patient.

Lebhar-Friedman acquired Dowden in 2005, and is keeping Dowden's hospital marketing group and medical education business.

Lebhar-Friedman president Roger Friedman said that with the dropoff in journal ad pages and numerous blockbusters losing patent protection in the next few years, his company was looking for less exposure to advertising-dependent businesses. "We wanted to get away from products that were strictly advertising-based, and the professional journals group at Dowden was almost entirely advertising-based," said Friedman. "We'd rather be in databases, research, education -- more proprietary products."


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...